Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	8.58B
Revenue (ttm)	7.48B
Net Income (ttm)	335.10M
Shares Out	11.66M
EPS (ttm)	27.37
PE Ratio	26.91
Forward PE	n/a
Dividend	0.75 (0.10%)
Ex-Dividend Date	Nov 14, 2025

Volume	4,200
Average Volume	3,710
Open	715.00
Previous Close	719.95
Day's Range	710.00 - 760.00
52-Week Range	611.05 - 1,288.50
Beta	0.25
RSI	54.88
Earnings Date	Feb 9, 2026

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceuticals products and allied products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical and consultancy services to various distributors and contract manufacturing services. The company offers tablet, hard and soft gelatine capsules, liquid and lyophilized injections, as well as pre-filled syringe, infusions, inhalers, nebulizers, nasal sprays and solutions, eye drops, creams, gels,...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 68
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.33% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 41.67%.